Among genes with significantly recurrent somatic mutations in cervical cancer, the mutation frequency of PIK3CA encoding the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit is relatively highly ranked, suggesting that targeted therapy against PIK3CA mutations may improve upon current strategies for the treatment of cervical cancer [3, 4]. This evidence concerns the gene PIK3CA and cervical cancer.